EUVIMEDEUVIMED entdecken
Crossref

Outcome of Subsequent Therapies After 177 Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience

Meryam Losee, Michael Kavanaugh, Mofei Liu, Nuno Borges, Veronica Haberman, Jolivette Ritzer, Andrew Wolanski, Sudhir Bhimaniya, Atish D Choudhury iD, Hyewon Hyun, Hailey Stoltenberg, Kerry L Kilbridge und 10 weitere

The Prostate · 2025-06 · 85 (8) · 742-748

DOI: 10.1002/pros.24880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 18.03.2025. Verfasst von Meryam Losee und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Dipeptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: NIBIB NIH HHS, NIDDK NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

177 Lu‐vipivotide tetraxetan ( 177 Lu‐PSMA‐617, LuPSMA) improves overall survival in patients with metastatic castration‐resistant prostate cancer (mCRPC) after at least one taxane chemotherapy and androgen receptor pathway inhibitor. There are limited data on the clinical course and outcomes of patients with mCRPC after receipt of LuPSMA.

Methods

We queried an IRB‐approved prospectively maintained registry of all patients with mCRPC who received standard‐of‐care LuPSMA at our institution between June 2022 and January 2024. Clinical data about LuPSMA and subsequent therapies were extracted from the electronic medical record, including the type and number of subsequent systemic therapies, reason for treatment cessation, hematologic toxicity and supportive treatment, and PSA50 response to subsequent therapy (defined as a ≥ 50% decrease in PSA).

Results

A total of 146 patients were evaluated; mean age 72 (range 52–87), observed median follow‐up 5.9 months (range 0.51–18.7). Forty‐four received systemic treatment after LuPSMA. The most common subsequent treatment after LuPSMA was chemotherapy ( n = 27), primarily cabazitaxel ± carboplatin/cisplatin ( n = 23), and the median number of cycles received was 4 (range 1–7). In 35/44 men with available hematologic toxicity data, 13 developed grade ≥ 3 anemia, 7 had ≥ grade 3 thrombocytopenia, and 16 received hematologic support. PSA50 to post‐LuPSMA treatment occurred in 10/36 (28%) evaluable patients. Median overall survival from subsequent systemic therapy was 7.6 months (95% CI 5.81–NR).

Conclusions

30% of patients receiving standard‐of‐care LuPSMA received subsequent therapy, mostly cabazitaxel‐containing regimens. Post‐LuPSMA treatment appeared tolerable and was associated with a PSA50 response rate of 28%. These outcomes may be biased by limited standard‐of‐care life‐prolonging treatment options at the time of LuPSMA FDA approval, but it also highlights the continued need to develop novel therapeutic strategies for mCRPC post‐LuPSMA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHeterocyclic Compounds, 1-RingDipeptidesHumansMaleAgedMiddle AgedAged, 80 and overTreatment OutcomeTertiary Care CentersLutetiumRadioisotopesNeoplasm MetastasisProstate-Specific Antigen

Stichwörter der Autor:innen

177Lu‐PSMA‐617PSMAcastration‐resistant prostate cancerlutetiummCRPC

Substanzen

Heterocyclic Compounds, 1-RingPluvictoLutetiumRadioisotopesDipeptidesLutetium-177Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Radiology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

ORCID-Profile: Atish D Choudhury, Praful Ravi, Heather Jacene

Förderung

  • NIBIB NIH HHS
  • NIDDK NIH HHS
  • NCI NIH HHS

Zitieren

APA

Losee, M., Kavanaugh, M., Liu, M., Borges, N., Haberman, V., Ritzer, J., Wolanski, A., Bhimaniya, S., Choudhury, A. D., Hyun, H., Stoltenberg, H., Kilbridge, K. L., Morgans, A., Pomerantz, M., Robertson, M., Sakellis, C., Shah, H., Taplin, M. E., Wei, X. X., …, & Jacene, H. (2025). Outcome of Subsequent Therapies After 177 Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience. The Prostate, 85(8), 742-748. https://doi.org/10.1002/pros.24880

Vancouver

Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, et al. Outcome of Subsequent Therapies After 177 Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience. The Prostate. 2025;85(8):742-748. doi:10.1002/pros.24880

BibTeX
@article{Losee2025,
  author = {Losee, Meryam and Kavanaugh, Michael and Liu, Mofei and Borges, Nuno and Haberman, Veronica and Ritzer, Jolivette and Wolanski, Andrew and Bhimaniya, Sudhir and Choudhury, Atish D and Hyun, Hyewon and Stoltenberg, Hailey and Kilbridge, Kerry L and Morgans, Alicia and Pomerantz, Mark and Robertson, Matthew and Sakellis, Christopher and Shah, Hina and Taplin, Mary-Ellen and Wei, Xiao X and Ng, Thomas and Ravi, Praful and Jacene, Heather},
  title = {Outcome of Subsequent Therapies After 177 Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience},
  journal = {The Prostate},
  year = {2025},
  volume = {85},
  number = {8},
  pages = {742--748},
  doi = {10.1002/pros.24880}
}
Kostenlos starten →